Trial Profile
A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs Ferric maltol (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms AEGIS-1
- Sponsors Iron Therapeutics
- 26 Oct 2022 Results of pooled analysis assessing efficacy assessment of ferric maltol in the treatment of iron deficiency anemia at Week 4, to evaluate early response, and at Week 12 from the combined phase 3 AEGIS 1 and 2 (301/2) studies, and a phase 3b study (304), which included adults with a diagnosis of Crohns disease or ulcerative colitis, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.
- 11 Oct 2022 Results of a post-hoc analysis (NCT01340872 and NCT02680756) assessing quality of life in patients with Inflammatory bowel disease and Iron deficiency anaemia presented at the 30th United European Gastroenterology Week
- 27 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.